Muutke küpsiste eelistusi

Sphingolipid Metabolism and Metabolic Disease 1st ed. 2022 [Pehme köide]

  • Formaat: Paperback / softback, 213 pages, kõrgus x laius: 254x178 mm, kaal: 515 g, 1 Illustrations, black and white; VIII, 213 p. 1 illus., 1 Paperback / softback
  • Sari: Advances in Experimental Medicine and Biology 1372
  • Ilmumisaeg: 05-May-2023
  • Kirjastus: Springer Verlag, Singapore
  • ISBN-10: 9811903964
  • ISBN-13: 9789811903960
Teised raamatud teemal:
  • Pehme köide
  • Hind: 150,61 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Tavahind: 177,19 €
  • Säästad 15%
  • Raamatu kohalejõudmiseks kirjastusest kulub orienteeruvalt 2-4 nädalat
  • Kogus:
  • Lisa ostukorvi
  • Tasuta tarne
  • Tellimisaeg 2-4 nädalat
  • Lisa soovinimekirja
  • Formaat: Paperback / softback, 213 pages, kõrgus x laius: 254x178 mm, kaal: 515 g, 1 Illustrations, black and white; VIII, 213 p. 1 illus., 1 Paperback / softback
  • Sari: Advances in Experimental Medicine and Biology 1372
  • Ilmumisaeg: 05-May-2023
  • Kirjastus: Springer Verlag, Singapore
  • ISBN-10: 9811903964
  • ISBN-13: 9789811903960
Teised raamatud teemal:
This book provides an up-to-date review of the fundamentals of sphingolipid metabolism and its role in metabolic diseases. Focusing on the sphingolipid de novo synthesis pathway, the effect of sphingomyelin, ceramide, and sphingosine-1-phosphate, and linkage between sphingolipids and other lipids, such as cholesterol, it covers serine palmitoyltransferase, ceramide synthases, ceramidases, sphingosine kinases, and sphingomyelin synthases, and more. While highlighting how rare diseases related to abnormal glycosphingolipid metabolism, this publication introduces sphingolipid metabolism-related diseases, such as lung diseases and cancers, as well as sphingolipid circadian regulation. The book demonstrates advances and limitations of research on sphingolipid metabolism and its roles in metabolic diseases and other diseases. It offers graduate students and researchers a coherent overview of sphingolipids, as well as the limitations of current research in the field, and promotes further studies on metabolic diseases, as well as pharmaceutical research on drug discovery based on sphingolipid de novo synthase.
Chapter 1: Sphingolipids and Cholesterol.
Chapter 2: Sphingolipids in
adipose: kin or foe?.
Chapter 3: De novo sphingolipid biosynthesis in
atherosclerosis.
Chapter 4: Serine Palmitoyltransferase Subunit 3 and
Metabolic Diseases.
Chapter 5: Molecular mechanisms of sphingolipid
transport on plasma lipoproteins.
Chapter 6: Sphingosine 1-phosphate
metabolism and signaling.
Chapter 7: Sphingomyelin synthase family and
phospholipase Cs.
Chapter 8: Sphingolipid metabolism and signaling in
endothelial cell functions.
Chapter 9: Cholesterol metabolism in chronic
kidney disease: physiology, pathologic mechanisms, and treatment.- Chapter
10: Sphingolipids and asthma.- Chaper 11: Manifold Roles of Ceramide
Metabolism in Nonalcoholic Fatty Liver Disease and Liver Cancer.
Chapter 12:
Drug development in the field of sphinogolipid metabolism.
Chapter 13: Rare
diseases in glycosphingolipid metabolism.
Dr. Xian-Cheng Jiang (PhD) is a Distinguished Professor at the State University of New York (SUNY). He is working at the Department of Cell Biology, SUNY Downstate Health Sciences University. His research focuses on lipid metabolism and metabolic diseases, such as atherosclerosis, metabolic syndrome, obesity and liver steatosis, particularly how sphingolipid metabolism influences plasma lipoprotein metabolism, cell membrane lipid composition and function, and the development of metabolic diseases.